Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5519021 | GILEAD SCIENCES | Benzoxazinones as inhibitors of HIV reverse transcriptase |
May, 2013
(10 years ago) | |
US5814639 | GILEAD SCIENCES | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep, 2015
(8 years ago) | |
US5914331 | GILEAD SCIENCES | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul, 2017
(6 years ago) | |
US5922695 | GILEAD SCIENCES | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jul, 2017
(6 years ago) | |
US5935946 | GILEAD SCIENCES | Nucleotide analog composition and synthesis method |
Jul, 2017
(6 years ago) | |
US5977089 | GILEAD SCIENCES | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(6 years ago) | |
US6939964 | GILEAD SCIENCES | Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
Jan, 2018
(6 years ago) | |
US6639071 | GILEAD SCIENCES | Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
Feb, 2018
(6 years ago) | |
US6703396 | GILEAD SCIENCES | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar, 2021
(3 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5811423 | GILEAD SCIENCES | Benzoxazinones as inhibitors of HIV reverse transcriptase |
Aug, 2012
(11 years ago) | |
US5519021 (Pediatric) | GILEAD SCIENCES | Benzoxazinones as inhibitors of HIV reverse transcriptase |
Nov, 2013
(10 years ago) | |
US5663169 | GILEAD SCIENCES | Benzoxazinones as inhibitors of HIV reverse transcriptase |
Sep, 2014
(9 years ago) | |
US5663169 (Pediatric) | GILEAD SCIENCES | Benzoxazinones as inhibitors of HIV reverse transcriptase |
Mar, 2015
(9 years ago) | |
US5814639 (Pediatric) | GILEAD SCIENCES | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Mar, 2016
(8 years ago) | |
US6043230 | GILEAD SCIENCES | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(6 years ago) | |
US5914331 (Pediatric) | GILEAD SCIENCES | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jan, 2018
(6 years ago) | |
US5935946 (Pediatric) | GILEAD SCIENCES | Nucleotide analog composition and synthesis method |
Jan, 2018
(6 years ago) | |
US5977089 (Pediatric) | GILEAD SCIENCES | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(6 years ago) | |
US6043230 (Pediatric) | GILEAD SCIENCES | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(6 years ago) | |
US5922695 (Pediatric) | GILEAD SCIENCES | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jan, 2018
(6 years ago) | |
US6939964 (Pediatric) | GILEAD SCIENCES | Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
Jul, 2018
(5 years ago) | |
US6639071 (Pediatric) | GILEAD SCIENCES | Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
Aug, 2018
(5 years ago) | |
US6642245 | GILEAD SCIENCES | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov, 2020
(3 years ago) | |
US6642245 (Pediatric) | GILEAD SCIENCES | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
May, 2021
(2 years ago) | |
US6703396 (Pediatric) | GILEAD SCIENCES | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Sep, 2021
(2 years ago) | |
US8592397 | GILEAD SCIENCES | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
US9744181 | GILEAD SCIENCES | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
US8716264 | GILEAD SCIENCES | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
US9457036 | GILEAD SCIENCES | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
US8716264 (Pediatric) | GILEAD SCIENCES | Compositions and methods for combination antiviral therapy |
Jul, 2024
(2 months from now) | |
US9545414 | GILEAD SCIENCES | Unitary pharmaceutical dosage form |
Jun, 2026
(2 years from now) | |
US9018192 | GILEAD SCIENCES | Unitary pharmaceutical dosage form |
Jun, 2026
(2 years from now) | |
US8598185 | GILEAD SCIENCES | Unitary pharmaceutical dosage form |
Apr, 2029
(5 years from now) |
Atripla is owned by Gilead Sciences.
Atripla contains Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate.
Atripla has a total of 33 drug patents out of which 29 drug patents have expired.
Expired drug patents of Atripla are:
Atripla was authorised for market use on 12 July, 2006.
Atripla is available in tablet;oral dosage forms.
Atripla can be used as treatment of hiv-1 infection in adults, treatment of hiv-1 infection in pediatric patients 12 years of age and older, treatment of hiv infection.
The generics of Atripla are possible to be released after 28 April, 2029.
Drugs and Companies using EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient
Market Authorisation Date: 12 July, 2006
Treatment: Treatment of hiv-1 infection in adults; Treatment of hiv-1 infection in pediatric patients 12 years of age and older; Treatment of hiv infection
Dosage: TABLET;ORAL